Exelixis announces CSO transition; Peter Lamb steps down; Dana Aftab promoted

EXELIXIS, INC.

Peter Lamb transitions from CSO to EVP, Scientific Strategy effective December 15, 2022.
Dana T. Aftab, Ph.D., appointed as new CSO and EVP, Discovery and Translational Research.
Dr. Aftab has over 24 years at Exelixis, most recently EVP, Business Operations.
He previously led discovery and development of cabozantinib and streamlined translational processes.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Peter Lamb

Executive Vice President, Scientific Strategy

EXEL · EXELIXIS, INC.

Effective: 2022-12-15
Successor: Dana T. Aftab
Filed: December 15, 2022, 6:59 PM ET

Peter Lamb, Ph.D., currently, Executive Vice President, Scientific Strategy and Chief Scientific Officer of Exelixis, Inc. (“Exelixis” or the “Company”), will transition into a new role as Executive Vice President, Scientific Strategy, effective as of today.

Appointed

Dana T. Aftab

Chief Scientific Officer

EXEL · EXELIXIS, INC.

Effective: 2022-12-15
Filed: December 15, 2022, 6:59 PM ET

Dana T. Aftab, Ph.D., will become the Company’s next Chief Scientific Officer and will also serve as Executive Vice President, Discovery and Translational Research.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Peter Lamb changed role as Executive Vice President, Scientific Strategy at EXELIXIS, INC..

Action: transitioned
Role: Executive Vice President, Scientific Strategy

Exact text from the filing

Peter Lamb, Ph.D., currently, Executive Vice President, Scientific Strategy and Chief Scientific Officer of Exelixis, Inc. (“Exelixis” or the “Company”), will transition into a new role as Executive Vice President, Scientific Strategy, effective as of today.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Dana T. Aftab was appointed as Chief Scientific Officer at EXELIXIS, INC..

Action: appointed
Role: Chief Scientific Officer

Exact text from the filing

Dana T. Aftab, Ph.D., will become the Company’s next Chief Scientific Officer and will also serve as Executive Vice President, Discovery and Translational Research.

View on SEC.gov

EXELIXIS, INC. filing history →

Source: SEC EDGAR

accession 0000939767-22-000121

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.